Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Incretins show little effect on insulin clearance in type 2 diabetes
Última actualización 12 de septiembre de 2026
Key finding
Insulin clearance showed some differences between sitagliptin and metformin treatment (p < 0.02).
This randomized controlled trial investigated the effects of incretin-based therapies on insulin clearance in type 2 diabetes. It found significant differences in insulin clearance between treatments.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This randomized controlled trial investigated the effects of incretin-based therapies on insulin clearance in type 2 diabetes. It found significant differences in insulin clearance between treatments.
Clinical relevance
Understanding how different diabetes medications impact insulin clearance is crucial for optimizing treatment strategies in type 2 diabetes. The findings may help clinicians tailor therapies to improve patient outcomes, particularly in managing blood glucose levels and insulin sensitivity.
Keep in mind
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Andrea T, Christian G, Irfan V, Giovanni P, Michael N. Incretins and insulin clearance in type 2 diabetes: a randomized controlled trial. Scientific Reports. 2022;12:2510. doi:10.1038/s41598-022-06402-5
Efectos Principales
Insulin clearance showed significant differences between sitagliptin and metformin (p < 0.02).
Total insulin secretion was significantly higher during OGTT compared to IIGI (p < 0.0001).
Plasma glucose levels were significantly reduced during the intervention (p < 0.01).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to GIP, GLP-1 receptor agonists, GLP-1/GIP Combination, and 3 more and C-peptide, Blood glucose, Total GIP, and 3 more.
This study contributes evidence to
Primary intervention
GIP
Primary outcomes
- C-peptide
- Blood glucose
- Total GIP
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
7
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
7
Related topics
7
Evidence pairs
1488
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 7 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Fasting Glucose
Evidencia relacionada
Tema de evidencia
Insulin Resistance
Guardar evidencia
Tema de evidencia
C-Peptide
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTotal insulin secretion
Metformin/Sitagliptin Combination → Total insulin secretion
Metformin/Sitagliptin Combination → Total insulin secretion
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Insulin clearance differed significantly between sitagliptin and metformin (p < 0.02).
- Total insulin secretion increased significantly during OGTT (p < 0.0001).
- Plasma glucose levels decreased significantly during the intervention.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Participants undergoing treatment with incretin-based therapies.
Tener en Cuenta
- Results may not apply to populations outside the study's demographics.
- Findings are based on a specific set of interventions and may not generalize to all diabetes treatments.
- Further studies are needed to explore long-term effects and broader applications.
Entre Líneas
- Limited sample size may affect generalizability.
- Short duration of the study may not capture long-term effects.
- Potential confounding factors were not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Insulin Resistance, GIP and C-peptide Levels.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → Insulin Resistance
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 4 estudios
View evidenceMedications
GIP → C-peptide Levels
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Insulin Resistance Evidence Hub
All studies measuring Insulin Resistance
4 studies
outcome_hubMeasures Insulin Resistance as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
4 studies
intervention_hubContributes to Metformin Therapies evidence base.
C-peptide Levels Evidence Hub
All studies measuring C-peptide Levels
1 studies
outcome_hubMeasures C-peptide Levels as a key outcome.
GIP Evidence Hub
All studies on GIP
1 studies
intervention_hubContributes to GIP evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and Insulin sensitivity
Intervention: MetforminOutcome: Insulin sensitivity
4 results
All studies on GIP and C-peptide
Intervention: GIPOutcome: C-peptide
1 results
All studies on Metformin
Intervention: Metformin
4 results
All studies on GIP
Intervention: GIP
1 results
All studies measuring Insulin sensitivity
Outcome: Insulin sensitivity
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve fasting glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.
Does GLP-1/GIP Combination improve total gip?
Emerging Evidence
GLP-1/GIP Combination appears to improve total gip.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Total GIP
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does GLP-1/GIP Combination improve total glp-1?
Emerging Evidence
GLP-1/GIP Combination appears to improve total glp-1.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Total GLP-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Metformin/Sitagliptin Combination improve total insulin secretion?
Emerging Evidence
Metformin/Sitagliptin Combination appears to improve total insulin secretion.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Total insulin secretion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dietary Modulation of Gut Microbiota in PrediabetesSitagliptin improves kidney function in type 1 diabetesVildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesEarly use of effective therapies may improve diabetes outcomesMetformin improves glycemic control in adolescents with type 1 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.